Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.56 |
| ▸ | CA12 | O43570 | 11/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.56 |
| ▸ | GLA | P06280 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | CASP1 | P29466 | 3/20 | 0.56 |
| ▸ | CASP7 | P55210 | 3/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203277 | 0.78 | CA9 (0.47) | CA9CA12MCL1KDM4EGAA | |
| SCHEMBL5200967 | 0.78 | CA12 (0.47) | CA9CA12MCL1KDM4EGAA | |
| SCHEMBL5204008 | 0.78 | ALDH1A1 (0.50) | CA9CA12MCL1KDM4EGAA | |
| SCHEMBL5201844 | 0.77 | CA9 (0.50) | CA9CA12MCL1KDM4EGAA | |
| SCHEMBL5202137 | 0.74 | PGR (0.47) | CA9CA12MCL1KDM4EGAA | |
| Umbelliferone SCHEMBL11137587 | 0.72 | CA9 (1.00) | CA9CA12MCL1KDM4EGAA | |
| Esculetin SCHEMBL24641 | 0.72 | CA9 (1.00) | CA9CA12MCL1KDM4EGAA | |
| Esculetin SCHEMBL29569228 | 0.72 | CA9 (1.00) | CA9CA12MCL1KDM4EGAA | |
| Esculetin SCHEMBL6867015 | 0.72 | CA9 (1.00) | CA9CA12MCL1KDM4EGAA | |
| Umbelliferone SCHEMBL29396070 | 0.72 | CA9 (1.00) | CA9CA12MCL1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174960-B2 | Compounds useful against kinetoplastideae parasites | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-11-03 | — | — | US | disclosed |
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-08-23 | — | — | US | disclosed |
| EP-2477698-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | Centre National de la Recherche Scientifique (FR) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011033115-A2 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-03-24 | — | — | WO | disclosed |
| EP-0998474-B1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-0998474-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999003855-A1 | PIPERAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214996-A1 | COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES | TST, PDXK, TBCB | CA9 4862/4885CA12 4875/4885MCL1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.